Mass General Brigham one of the United States’ largest academic medical systems has announced the formation of AIwithCare, a new independent company dedicated to scaling its AI-powered clinical trial screening solution for broader commercial use. The venture marks a strategic shift from a purely internal research tool to a product aimed at hospitals, research institutions and life-science organisations seeking to enhance clinical trial efficiency and patient matching.

The AIwithCare platform originated from innovation efforts within Mass General Brigham’s technology ecosystem. It leverages natural language processing (NLP) and machine learning algorithms to comb through vast amounts of clinical data including unstructured text in EHRs, lab results and demographic records and then matches patients against complex clinical trial criteria. This process greatly reduces the manual effort currently required for patient pre-screening, a critical bottleneck that often slows trial start-up and timely enrolment.

Recruitment delays are a persistent challenge in clinical research worldwide, with many trials unable to meet enrolment targets on time, delaying innovation and increasing study costs. By automating and enhancing the precision of candidate identification, AIwithCare is designed to help trial sponsors and centres accelerate timelines, improve diversity of enrolment, and reduce the administrative barrier that clinicians face when evaluating trial eligibility during routine care.

The spin-out is also expected to support real-time trial matching during patient visits, enabling clinicians to discuss potential research participation at the point of care, rather than relying on separate recruitment workflows. Mass General Brigham leadership says that commercial adoption of the AIwithCare platform could help transform how experimental therapies are tested globally bridging the gap between clinical care and research while enabling more people to benefit from cutting-edge treatments.